



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, 27 March 2025, 25 April 2025, and 8 May 2025 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Catalist Rules, the Board wishes to update shareholders that in relation to the declaration of a dividend *in specie* of Resilient Medical comprising 2,000,000 ordinary shares in the issued share capital of RMKH SG to the Company as disclosed in the Announcements, the legal transfer of the entire issued share capital of RMKH SG from Resilient Medical to the Company has been completed on 28 May 2025. Following the completion of the share transfer, RMKH SG is a direct wholly-owned subsidiary of the Company.

3. FINANCIAL IMPACT

As RMKH SG is now a wholly-owned subsidiary of the Company, the Company will consolidate both RMKH SG and RMKH Cambodia into the Group's financial statements. Based on our assessment, this consolidation will not have a material impact on the Group's financial position or results.

As at the date of this announcement, the Company is still assessing the impact of the declaration of the dividend *in specie* of shares of RMKH SG on the net tangible assets per share of the Company and the earnings per share of the Company for the current financial year ending 31 December 2025, as further discussions with the Liquidator are necessary to determine the extent of potential recoveries.

The Company is supportive of the Distribution as the Distribution will reduce the debt owed by Resilient Medical to the Company. More importantly, the Distribution enables the Company to obtain full legal and shareholder control of RMKH SG, and by extension, of RMKH Cambodia. This formalises the Company's position as both the legal and beneficial controller of RMKH Cambodia, reinforcing its ability to direct the subsidiary's future strategic and operational development.

The Company notes that its management team has consistently maintained operational oversight and control of RMKH Cambodia, including during the period of Resilient Medical's liquidation. As a result, the Company has continued to ensure that RMKH Cambodia's manufacturing assets remain in good condition and operationally ready.

In addition, RMKH Cambodia's production lines have been upgraded and enhanced to improve manufacturing efficiency and product quality. These improvements and the Company's continued operational stewardship have positioned RMKH Cambodia to resume or expand production efficiently as and when regional demand increases.

In the event that there is any further material development on this matter, the Company will make a separate announcement in due course.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical, as well as any orders, directions or declarations as may be made by the Liquidator from time to time, in between the monthly updates.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 28 May 2025 to the SGX-ST.

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms. Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.